INTRODUCTION:
The oral route is considered as the most promising route of drug delivery. Effective oral drug delivery may depend upon the factors such as gastric several physiological limitations such as variable gastrointestinal transit, because of variable gastric emptying leading to non-uniform absorption profiles, incomplete drug release and shorter residence time of the dosage form in the stomach. This leads to incomplete absorption of drug shaving absorption window especially in the upper part of the small intestine, as once the drug passes down the absorption site, the remaining quantity goes unabsorbed. The Gastric emptying of dosage forms in humans factors because of which wide inter and are affected by several intra-subject variations are observed 1 . Since many drugs are well absorbed in the upper part of the gastrointestinal tract, such high vari-ability may lead to non-uniform absorption and makes the bioavailability unpredictable. Hence a beneficial delivery system would be one which possesses the ability to control and prolong the gastric emptying time and can deliver drugs in higher concentrations to the absorption site (i.e. upper part of the small intestine). Metformin HCl is an orally administered biguanide derivative widely used in the treatment of non-insulin dependent diabetes mellitus. It improves the glycemic control by enhancing insulin sensitivity in liver and muscles. Metformin also has beneficial effect on several cardiovascular risk factors such as dyslipidemia, elevated plasma-plasminogen activator inhibitor, other fibrinolytic abnormalities, and hyper insulenimia, and insulin resisance 2. Oral administration is the most convenient and preferred means of any drug delivery to the systematic circulation. Oral controlled release drug delivery have recently been of increasing interest in pharmaceutical field to achieve improved therapeutic advantages, such as ease of dosing administration, patient compliance and flexibility in formulation. Drugs that are easily absorbed from gastrointestinal tract (GIT) and have short half-lives are eliminated quickly from the systemic circulation. Frequent dosing of these drugs is required to achieve suitable therapeutic activity. To avoid this limitation, the development of oral sustained-controlled release formulations is an attempt to release the drug slowly into the gastrointestinal tract (GIT) and maintain an effective drug concentration in the systemic circulation for a long time.
After oral administration, such a drug delivery would be retained in the stomach and release the drug in a controlled manner, so that the drug could be supplied continuously to its absorption sites in the gastrointestinal tract (GIT) 3 . These drug delivery systems suffer from mainly two adversities: the short gastric retention time (GRT) and unpredictable short gastric emptying time (GET), which can result in incomplete drug release from the dosage form in the absorption zone (stomach or upper part of small intestine) leading to diminished efficacy of administered dose 4 . Procedure of pre-optimization study
MATERIAL AND METHODS

Preparation of tablets by wet granulation technique
Floating matrix tablets containing of Metformin HCl were prepared using wet granulation method using HPMC K 100 M, K 200 M and carbopol 971 P as polymer. All ingredients and d drug weight individually passed through sieve no 30, mixed and granulated with 10% solution of PVP K 30 in water. The wet mass was passed through the sieve no 16 and dried rapid dryer at 30°C for 25min at 30cfm to control a final LOD of about NMT 2.0% w/w. Dried granules were passed through the sieves no 40G using Ganson's Co-Mill and were mixed with weight quantity of sodium bicarbonate, lubricated with magnesium stearate and glidant colloidal silicon dioxide.
Compression force was kept constant throughout the study. Compression was carried out for final blend by using CADMAC 16 x 9.5 mm oval shaped with logo deposed on upper punch (D tooling). The project leads to a method for preparing an extended release tablet formulation of 500mg Metformin HCl. A unique blend of matrix system was used as a base for retarded release of drug. Two different grades of hydroxypropylmethyl cellulose (HPMC K100 LV and HPMC K 200 M) were mixed in different ratio to obtain a suitable matrix system for achieving the extended release profile of the said Metformin HCl. There are two independent variables and three responses in the formulation designing process. A 3 2 central composite design was employed for the purpose. Table 6 : depicts the detailed composition of formulations prepared as per the optimization design. 
Pre-Compression Evaluation
Evaluation of Powder Blends
Bulk density:
Bulk density was calculated from the formula given below.
Bulk density (g /ml) =
Weight of the blend
Bulk volume of the blend
Tapped Density:
Tapped density was calculated from the formula below.
Tapped density (g/ml) =
Weight of the blend
Tapped volume of the blend
Measures of Powder Compressibility:
For poorer flowing materials, there are frequently greater inter-particle interactions, and a greater difference between the bulk and tapped densities were observed. These differences are reflected in the compressibility index and Hausner's ratio.
Carr's compressibility index=
Tapped denesity −bulk denesity Tapped denesity
×100
Hausner's ratio = 
W2=
Final weight of tablets.
Floating lag time and duration of floating:
9
Floating characteristics of the prepared formulations were determined using USP XXII paddle apparatus under sink conditions. 900ml of hydrochloric acid buffer pH 1.2 was used as medium and the temperature was maintained to 37±0.5ºC thought the study. The time between the introduction of tablet and its buoyancy on the gastric fluid required for the tablet to float on the gastric fluid (floating lag time) and the time during which dosages for measurement buoyant (duration of floating) were measured. The integrity of the test tablets was observed visually during study.
Effect of Hardness on Buoyancy Lag Time
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Formulation F1 to F5 was selected to study the effect of hardness on buoyancy lag time. The tablets of batch 6 were compressed at different compression pressures to get the hardness of 5kg/cm2, 6kg/cm2, 7kg/cm2, 8kg/cm2 and 9kg/cm2. The tablets were evaluated for buoyancy lag time. The method was same as mentioned in determination of lag time.
7. In-vitro swelling study 11 Tablets were weighed individually and placed separately in basket of dissolution medium containing hydrochloric acid buffer (pH 1.2) solutions 900 ml at 37±0.5°C. At 12 hours, the tablets were withdrawn from the basket and blotted with tissue paper to removed excess surface water and the swollen tablets were reweighed on analytical balance. Swelling index (SI) of tablets was calculated using the following formula:
% Swelling Index =
Wet weight − Dry weight
Wet weight × 100
In -Vitro Drug Release Studies
In-vitro dissolution studies were carried out in USP type-I (Basket) tablet dissolution apparatus using 900ml hydrochloric acid buffer pH 1.2 as dissolution media. The basket was rotated at 100 rpm and the temperature was maintained at 37±0.5°C throughout the study. Atprede termined time intervals 10 mL of the samples were withdrawn by means of an auto sampler machine with a pre filter. The volume withdrawn at each interval was replaced with same quantity of fresh dissolution medium maintained at 37±0.5°C. The samples were analyzed for drug releases by measuring the absorbance at 255 nm using HPLC method.
RESULTS AND DISCUSSION:
Particle Size Analysis of Metformin HCl:
Figure 1: Particle size distribution
The flow properties of powders are dependent upon the particle size distribution as well as particle shape. Asymmetric particles have poor flow characteristics and hence granulation techniques are used to convert blends of drug and other additives into particles of uniform size having good flow properties. X-ray diffraction study of pure drug was carried out and its high intensity diffraction peaks at 2θshowed sharp peaks as similar to standard Metformin HCl , both PXRD pattern showing crystalline nature as showed in figure (8,9) .
PREPARATION OF STANDARD CURVE OF Metformin HCl
Pre-Optimization Studies
Evaluation of the Metformin HCl: Physical evaluation of the Drug
The API of were tested by various studies including bulk density 0.45gm/ml), tapped density 0.56 gm/ml, Hausner's ratio 1.24 and Carr's index 19.64 %). All the results showed very-very poor flow property. Dissolution profile of DOE optimized gastroretentive formulation (F1-F9) and Marketed extended release formulation in hydrochloric acid (1.2 pH) compared and it was realized that all formulation (F1-F9) shown similar release profile as compared with Marketed extended release formulation, hence out of all formulation composition any of formulation can be chosen for further commercial scalability and production. From DOE optimization it also proves robustness range of process. Assay result of all formulation were observed in between (90 to 110%) of range.
Assay (BY HPLC) OF Metformin HCl Tablets
SELECTION OF THE OPTIMIZED FORMULATION
The optimized formulation was selected by trading off the various responses. Fig.17 Depicts the overlay plot showing the location of the optimized formulation. There is no significant fall observed in drug release profile of formulation F9 compared in initial and 3 month accelerated stability condition.
CONCLUSION
The main aim of the present dissertation was to develop novel Floating extended release formulation of Metformin HCl which is targeted to release drug till 12 hours at gastric region and compared the in-vitro similarity of novel formulation with already existing Marketed extended release formulation of Metformin HCl, which releases drug in intestinal region. Thus from the data obtained, it can be concluded that:
Gastroretentive dosage form of an antidiabetic drug of Metformin HCl formulated as an approach to increase gastric residence time and thereby minimizing hepatic extraction ratio followed by dangerous side effects. It was an effort to introduced sodium bicarbonate as effervescent agent in matrix based tablet, which tends to create buoyancy in formulation at gastric site, results tablet start floating in gastric region for sustained time period, thus release of drug at site of gastric mucosa in sustained way. Among the polymers used to improve the gastric residence, cellulose Polymers HPMC K100M, HPMC K200CR, showed better control over drug release than Carbopol 941P. Gastroretentive dosage form (Novel extended release formulation) are claiming to advantage to reduce dosing frequency over conventionally available IR formulation of 500 mg , 850 mg and 1000 mg recommended to two to three times daily leads to multiple dosing and patient incompliance as well as Potential side effects. Gastroretentive dosage form (Novel extended release formulation) is claiming to enhanced bioavailability and absorption of drug at site of gastric region. 
